LPCN — Lipocine Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1535955 ·
Last close
$1.93
Market Cap
$15.91M
52W High
$12.37
52W Low
$1.81
ADV30
3,634,673
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 190,099 | -1,851,290 | -2,842,246 | -2,622,595 | 23,835,361 | 4,979,430 | 2,067,957 |
| Mar 2026 | 119,397 | — | -3,849,464 | -3,671,894 | 25,358,166 | 5,015,608 | 2,527,843 |
| Dec 2025 | 1,145,390 | — | -2,515,801 | -2,370,084 | 17,005,612 | 5,205,842 | 2,528,196 |
| Sep 2025 | 114,574 | — | -3,361,040 | -3,186,832 | 16,073,167 | 3,901,040 | 1,931,119 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-11,190,794
Investing CF
$-6,146,470
Financing CF
$16,272,714
CapEx
$-10,019
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.86
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-215,690,856
Inventory
—
Receivables
$291,164
ST Investments
$18,287,179
EBIT TTM
$-12,568,551
Pretax Income TTM
$-11,851,205
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,569,460
EBITDA
$-12,509,986
Free Cash Flow
$-6,939,857
Enterprise Value
$-4,294,347
Total Cash
$23,266,608
Total Debt
$257,807
Shares Out
8,244,253
Trailing EPS
$-1.85
Book Value
$2.64
ROE
-60.9%
ROA
-37.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,976,677 | -10,371,379 | -9,627,505 | 17,005,612 | 2,528,196 | 14,477,416 | -9,760,721 |
| Dec 2024 | 11,198,144 | -1,155,035 | 8,352 | 22,510,501 | 1,512,936 | 20,997,565 | -1,221,233 |
| Dec 2023 | -2,850,818 | -17,930,957 | -16,352,082 | 23,001,072 | 2,631,629 | 20,369,443 | -11,865,991 |
| Dec 2022 | 500,000 | -12,119,375 | -10,758,636 | 37,542,922 | 1,907,982 | 35,634,940 | -11,968,819 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$2,002,210
NetIncome TTM
$-11,434,526
OpCashFlow TTM
—
Assets (Latest)
$25,358,166
Forward EPS
$-1.24
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MRKR | Marker Therapeutics, Inc. | $15.84M | $0.95 | — |
| AKTX | Akari Therapeutics Plc | $15.83M | $8.13 | — |
| PTN | PALATIN TECHNOLOGIES INC | $16.05M | $9.01 | — |
| RADX | Radiopharm Theranostics Ltd | $16.05M | $1.11 | — |
| RKTO | Rocket One Inc. | $16.09M | $0.65 | — |
News headlines (Yahoo Finance, 1h cache)
Here's Why You Should Add LPCN Stock to Your Portfolio Now
2026-10-08 13:57 · Yahoo
Lipocine Health Canada Approval Clears TLANDO for Canadian Testosterone Replacement Market
2026-10-07 14:01 · Yahoo
Lipocine stock surges 30% on Health Canada drug approval
2026-10-07 13:24 · Yahoo
LPCN Stock Is Surging: Here’s Why Lipocine Is On Traders’ Radar Today
2026-10-07 12:44 · Yahoo
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy
2026-10-07 12:00 · Yahoo
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?
2026-09-23 16:00 · Yahoo
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-10 12:00 · Yahoo
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154
2026-06-04 12:00 · Yahoo
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
2026-05-19 12:00 · Yahoo
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase
2026-05-18 12:00 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-10-01 20:28:21 | 2026-09-29 | Higuchi John W. | Dir | P - Purchase | 2.2 | 25007 | 55043 |
| 2026-09-30 20:38:30 | 2026-09-28 | Higuchi John W. | Dir | P - Purchase | 2.16 | 12561 | 27132 |